Drug repurposing is an attractive strategy for extending the arsenal of oncology therapies. Screening of a large collection of existing non-oncology compounds against a panel of cancer cell lines now identifies several drugs capable of selectively inhibiting the growth of cancer cells.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Continuous Spatiotemporal Therapy of A Full-API Nanodrug via Multi-Step Tandem Endogenous Biosynthesis
Nature Communications Open Access 25 March 2023
-
Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis
Scientific Reports Open Access 28 September 2020
-
Overcoming cancer therapeutic bottleneck by drug repurposing
Signal Transduction and Targeted Therapy Open Access 02 July 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Corsello, S.M.N. Nat. Cancer https://doi.org/10.1038/s43018-019-0018-6 (2019).
Corsello, S. M. et al. Nat. Med. 23, 405–408 (2017).
Yu, C. et al. Nat. Biotechnol. 34, 419–423 (2016).
Garnett, M. J. et al. Nature 483, 570–575 (2012).
Basu, A. et al. Cell 154, 1151–1161 (2013).
Ghandi, M. et al. Nature 569, 503–508 (2019).
Barretina, J. et al. Nature 483, 603–607 (2012).
de Waal, L. et al. Nat. Chem. Biol. 12, 102–108 (2016).
Allensworth, J. L. et al. Mol. Oncol. 9, 1155–1168 (2015).
Peters, K. G. et al. J. Inorg. Biochem. 96, 321–330 (2003).
Clark, O. et al. Cancer Lett. 357, 316–327 (2015).
Argentieri, D. C. et al. J. Pharmacol. Exp. Ther. 271, 1399–1408 (1994).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Beijersbergen, R.L. Old drugs with new tricks. Nat Cancer 1, 153–155 (2020). https://doi.org/10.1038/s43018-020-0024-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-020-0024-8
This article is cited by
-
Continuous Spatiotemporal Therapy of A Full-API Nanodrug via Multi-Step Tandem Endogenous Biosynthesis
Nature Communications (2023)
-
Overcoming cancer therapeutic bottleneck by drug repurposing
Signal Transduction and Targeted Therapy (2020)
-
Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis
Scientific Reports (2020)